
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/251560/publications.pdf Version: 2024-02-01



IONAS REDCH

#	Article	IF	CITATIONS
1	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546.	0.6	1,449
2	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 2017, 377, 1836-1846.	13.9	1,052
3	A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 2009, 15, 68-74.	15.2	566
4	Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. Journal of Clinical Oncology, 2017, 35, 1641-1649.	0.8	555
5	Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nature Communications, 2018, 9, 5150.	5.8	496
6	Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 386, 433-443.	6.3	444
7	Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. Journal of Clinical Oncology, 2012, 30, 2601-2608.	0.8	411
8	An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell, 2017, 32, 669-683.e5.	7.7	352
9	Caring for patients with cancer in the COVID-19 era. Nature Medicine, 2020, 26, 665-671.	15.2	269
10	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€~298 women with early breast cancer in 26 randomised trials. Lancet, The, 2019, 393, 1440-1452.	6.3	260
11	FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1919-1925.	0.8	248
12	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. Journal of Clinical Oncology, 2012, 30, 921-929.	0.8	244
13	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene, 2018, 37, 4639-4661.	2.6	219
14	Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer. American Journal of Pathology, 2009, 175, 334-341.	1.9	215
15	Digital image analysis outperforms manual biomarker assessment in breast cancer. Modern Pathology, 2016, 29, 318-329.	2.9	144
16	Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. Nature Communications, 2019, 10, 2110.	5.8	139
17	CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. Journal of Clinical Investigation, 2020, 130, 1185-1198.	3.9	139
18	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	0.5	133

#	Article	IF	CITATIONS
19	Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. Journal of Clinical Investigation, 2018, 128, 1355-1370.	3.9	123
20	<i>Increased Expression of N</i> -myc <i>in Human Small Cell Lung Cancer Biopsies Predicts Lack of Response to Chemotherapy and Poor Prognosis</i> . American Journal of Clinical Pathology, 1987, 88, 216-220.	0.4	91
21	Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial. Breast Cancer Research and Treatment, 2018, 169, 93-103.	1.1	86
22	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
23	Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Research and Treatment, 2016, 160, 131-143.	1.1	82
24	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. JAMA - Journal of the American Medical Association, 2016, 316, 1888.	3.8	79
25	miRâ€206 inhibits cell migration through direct targeting of the actinâ€binding protein Coronin 1C in tripleâ€negative breast cancer. Molecular Oncology, 2014, 8, 1690-1702.	2.1	77
26	Detection of tumor-specific cytotoxic drug activityIN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. International Journal of Cancer, 1994, 56, 715-720.	2.3	71
27	Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data. Clinical Cancer Research, 2019, 25, 5717-5726.	3.2	71
28	Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer. Histopathology, 2018, 72, 974-989.	1.6	70
29	High-intensity exercise during chemotherapy induces beneficial effects 12Âmonths into breast cancer survivorship. Journal of Cancer Survivorship, 2019, 13, 244-256.	1.5	65
30	Expression of multiple growth factors in a human lung cancer cell line. International Journal of Cancer, 1987, 39, 502-507.	2.3	59
31	Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer—a prospective nationwide Swedish multicenter study. Human Reproduction, 2020, 35, 929-938.	0.4	58
32	Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells. Journal of the National Cancer Institute, 2015, 107, djv209.	3.0	57
33	Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. British Journal of Cancer, 2016, 114, 1117-1124.	2.9	57
34	STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. Cancers, 2019, 11, 1479.	1.7	55
35	Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer. Cancer Research, 2015, 75, 2445-2456.	0.4	53
36	Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4956-4962.	0.8	52

#	Article	IF	CITATIONS
37	Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. Cancers, 2019, 11, 628.	1.7	51
38	Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages. Cancer Research, 2016, 76, 3166-3178.	0.4	48
39	The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. Breast Cancer Research, 2019, 21, 34.	2.2	48
40	Quo Vadis With Targeted Drugs in the 21st Century?. Journal of Clinical Oncology, 2009, 27, 2-5.	0.8	45
41	mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. Cancer Letters, 2015, 367, 76-87.	3.2	45
42	Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. Breast Cancer Research and Treatment, 2018, 167, 761-769.	1.1	45
43	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nature Cancer, 2022, 3, 251-261.	5.7	44
44	Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts. Clinical Cancer Research, 2017, 23, 7512-7520.	3.2	43
45	Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A populationâ€based cohort study. International Journal of Cancer, 2018, 143, 1093-1104.	2.3	40
46	Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. Breast Cancer Research, 2018, 20, 64.	2.2	40
47	Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 99, 102257.	3.4	40
48	RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clinical Breast Cancer, 2017, 17, 585-594.e4.	1.1	39
49	Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. IScience, 2018, 9, 71-83.	1.9	38
50	Immune gene expression and response to chemotherapy in advanced breast cancer. British Journal of Cancer, 2018, 118, 480-488.	2.9	37
51	Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast, 2012, 21, 507-513.	0.9	36
52	The European Cancer Patient's Bill of Rights, update and implementation 2016. ESMO Open, 2016, 1, e000127.	2.0	36
53	Separation of breast cancer and organ microenvironment transcriptomes in metastases. Breast Cancer Research, 2019, 21, 36.	2.2	36
54	A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment. Supportive Care in Cancer, 2017, 25, 1423-1429.	1.0	34

#	Article	IF	CITATIONS
55	The European Medicines Agency Approval of Axitinib (Inlyta) for the Treatment of Advanced Renal Cell Carcinoma After Failure of Prior Treatment With Sunitinib or a Cytokine: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Oncologist, 2015, 20, 196-201.	1.9	33
56	An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma. Cancer Immunology, Immunotherapy, 2019, 68, 927-936.	2.0	32
57	Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. Clinical Proteomics, 2015, 12, 8.	1.1	31
58	Timeâ€dependent risk and predictors of venous thromboembolism in breast cancer patients: A populationâ€based cohort study. Cancer, 2017, 123, 468-475.	2.0	31
59	Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study. Cancers, 2021, 13, 1166.	1.7	31
60	Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. Oncotarget, 2015, 6, 33306-33318.	0.8	31
61	Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer. JAMA Oncology, 2021, 7, 1360.	3.4	30
62	High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer. Journal of Pathology: Clinical Research, 2017, 3, 38-43.	1.3	29
63	Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancer. EBioMedicine, 2019, 48, 212-223.	2.7	29
64	Suramin in Non-small Cell Lung Cancer and Advanced Breast Cancer: Two Parallel Phase II Studies. Acta Oncológica, 1997, 36, 171-174.	0.8	28
65	Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines – a Swedish survey with central re-assessment. Acta Oncológica, 2015, 54, 1040-1048.	0.8	27
66	Assessment of early response biomarkers in relation to longâ€term survival in patients with HER2â€negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. International Journal of Cancer, 2018, 142, 618-628.	2.3	27
67	Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy. Acta Radiologica, 2017, 58, 394-402.	0.5	25
68	Breast cancer in young women and prognosis: How important are proliferation markers?. European Journal of Cancer, 2017, 84, 278-289.	1.3	24
69	MNK2 governs the macrophage antiinflammatory phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27556-27565.	3.3	24
70	A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels. Oncogene, 2020, 39, 5430-5440.	2.6	23
71	Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis. Journal of Infection, 2016, 72, 650-658.	1.7	22
72	Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs). BMC Cancer, 2018, 18, 174.	1.1	22

#	Article	IF	CITATIONS
73	CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance. Scientific Reports, 2019, 9, 19384.	1.6	22
74	Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. Molecular Oncology, 2016, 10, 517-525.	2.1	21
75	Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer. Journal of Clinical Pathology, 2018, 71, 787-794.	1.0	21
76	Amplification of the N-myc oncogene in an adenocarcinoma of the lung. Journal of Cellular Biochemistry, 1986, 31, 297-304.	1.2	20
77	The European Medicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2â€Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Oncologist, 2014, 19, 766-773.	1.9	20
78	Notch signaling promotes a HIF2α-driven hypoxic response in multiple tumor cell types. Oncogene, 2018, 37, 6083-6095.	2.6	20
79	Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 348-358.	2.5	20
80	Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Scientific Reports, 2017, 7, 1089.	1.6	19
81	Interventional Techniques for Bone and Musculoskeletal Soft Tissue Tumors: Current Practices and Future Directions - Part I. Ablation. Seminars in Musculoskeletal Radiology, 2020, 24, 692-709.	0.4	19
82	Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis?. Acta Oncológica, 2000, 39, 319-326.	0.8	18
83	Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. Oncolmmunology, 2018, 7, e1466017.	2.1	18
84	Programmed deathâ€ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21â€gene and 70â€gene signatures in estrogen receptorâ€positive disease. Molecular Oncology, 2020, 14, 951-963.	2.1	18
85	Impairment of endoxifen formation in tamoxifenâ€treated premenopausal breast cancer patients carrying reducedâ€function CYP2D6 alleles. British Journal of Clinical Pharmacology, 2021, 87, 1243-1252.	1.1	18
86	Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. Scientific Reports, 2016, 6, 38037.	1.6	17
87	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. Clinical Cancer Research, 2017, 23, 7225-7231.	3.2	17
88	A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncológica, 2011, 50, 35-41.	0.8	16
89	Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?. Journal of Clinical Oncology, 2016, 34, 1573-1579.	0.8	15
90	Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. Critical Reviews in Oncology/Hematology, 2017, 114, 91-101.	2.0	15

#	Article	IF	CITATIONS
91	Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. Clinical Cancer Research, 2017, 23, 2584-2592.	3.2	15
92	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast Cancer Research, 2021, 23, 8.	2.2	15
93	Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients. Pharmacogenomics, 2018, 19, 1259-1268.	0.6	14
94	Efficacy and safety of tailored and doseâ€dense adjuvant chemotherapy and trastuzumab for resected HER2â€positive breast cancer: Results from the phase 3 PANTHER trial. Cancer, 2020, 126, 1175-1182.	2.0	14
95	The value of anticancer drugs — a regulatory view. Nature Reviews Clinical Oncology, 2022, 19, 207-215.	12.5	14
96	Characterization of A U-937 subline which can be induced to differentiate in serum-free medium. International Journal of Cancer, 1992, 50, 153-160.	2.3	13
97	Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. Molecular Oncology, 2015, 9, 1384-1391.	2.1	13
98	Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?. Lancet, The, 2003, 362, 183-184.	6.3	12
99	The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe. ESMO Open, 2016, 1, e000004.	2.0	12
100	Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 5249-5255.	3.2	12
101	PD-1 protein and gene expression as prognostic factors in early breast cancer. ESMO Open, 2020, 5, e001032.	2.0	12
102	European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open, 2019, 4, e000570.	2.0	11
103	Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. Acta Oncológica, 2020, 59, 1382-1387.	0.8	11
104	Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. Oncologist, 2020, 25, e709-e715.	1.9	11
105	Risk of heart disease following treatment for breast cancer – results from a population-based cohort study. ELife, 2022, 11, .	2.8	11
106	Superficial scrapings from breast tumors is a source for biobanking and research purposes. Laboratory Investigation, 2014, 94, 796-805.	1.7	10
107	Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling. BMC Cancer, 2017, 17, 802.	1.1	10
108	Effect of <i>CYP2C19</i> and <i>CYP2D6</i> genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. Pharmacogenomics, 2018, 19, 1027-1037.	0.6	10

#	Article	IF	CITATIONS
109	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. Acta Oncológica, 2020, 59, 75-81.	0.8	10
110	Chemotherapy use near the end-of-life in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 181, 645-651.	1.1	10
111	An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors. Clinical Cancer Research, 2016, 22, 2417-2426.	3.2	8
112	Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts. Acta Oncológica, 2017, 56, 1143-1151.	0.8	8
113	Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer. Cardio-Oncology, 2021, 7, 20.	0.8	8
114	High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial. Clinical Cancer Research, 2021, 27, 3469-3477.	3.2	8
115	Interventional Techniques for Bone and Musculoskeletal Soft Tissue Tumors: Current Practices and Future Directions – Part II. Stabilization. Seminars in Musculoskeletal Radiology, 2020, 24, 710-725.	0.4	8
116	Adjuvant chemotherapy for breast cancer—"one fits all�. Breast, 2005, 14, 564-569.	0.9	7
117	Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology. Journal of Clinical Oncology, 2017, 35, 254-255.	0.8	7
118	European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma. ESMO Open, 2020, 5, e000798.	2.0	6
119	Long-term (up to 16Âmonths) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. Breast Cancer Research and Treatment, 2020, 181, 87-96.	1.1	6
120	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Research and Treatment, 2021, 189, 15-23.	1.1	6
121	Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer. Cancers, 2021, 13, 4655.	1.7	6
122	Effects of Interferons and Tumour Necrosis Factor-α on Human Lung Cancer Cell Lines and the Development of an Interferon-Resistant Lung Cancer Cell Line. Acta Oncológica, 1996, 35, 473-478.	0.8	5
123	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase Il trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment, 2018, 168, 349-355.	1.1	5
124	Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1. Acta Oncológica, 2020, 59, 825-832.	0.8	5
125	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. Cancer Research, 2022, 82, GS1-01-GS1-01.	0.4	5
126	Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. Cancers, 2022, 14, 1999.	1.7	5

#	Article	IF	CITATIONS
127	MICADo – Looking for Mutations in Targeted PacBio Cancer Data: An Alignment-Free Method. Frontiers in Genetics, 2016, 7, 214.	1.1	4
128	Is There a Role for Intensive Therapy in Breast Cancer?. Acta Oncológica, 1999, 38, 37-46.	0.8	3
129	Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34Âyears longitudinal data from the Stockholm–Gotland cancer registry. Breast Cancer Research and Treatment, 2018, 172, 703-712.	1.1	3
130	Long-Term Prognostication for 20 114 Women With Small and Node-Negative Breast Cancer â€, (T1abN0) . JNCI Cancer Spectrum, 2021, 5, pkaa084.	1.4	3
131	Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. Npj Breast Cancer, 2021, 7, 144.	2.3	3
132	Erratum to "How to treat male breast cancer―[The Breast 16S2 (2007) S147–S154]. Breast, 2008, 17, 3	190.9	2
133	Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based study. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 147-155.	1.8	2
134	CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma. Cancers, 2021, 13, 1175.	1.7	2
135	RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 1280-1281.	3.0	1
136	Feasibility of reusing time-matched controls in an overlapping cohort. Statistical Methods in Medical Research, 2018, 27, 1818-1829.	0.7	1
137	Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects. ESMO Open, 2020, 5, e000856.	2.0	1
138	Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. Breast Cancer Research and Treatment, 2021, 190, 451-462.	1.1	1
139	Chemotherapy of Breast Cancer. American Journal of Cancer, 2002, 1, 165-171.	0.4	0
140	Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies. Journal of Clinical Oncology, 2016, 34, 895-897.	0.8	0
141	Reply to A.Y. Lin. Journal of Clinical Oncology, 2017, 35, 121-122.	0.8	0
142	Safety and efficacy of eribulin in patients with advanced breast cancer treated outside of a clinical trial: A single institution experience Journal of Clinical Oncology, 2012, 30, e11510-e11510.	0.8	0
143	Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study. Breast Cancer Research and Treatment, 2022, , 1.	1.1	0